Bionano Genomics Inc (NASDAQ: BNGO) stock jumped 8.15% on Monday to $1.46 against a previous-day closing price of $1.35. With 1.91 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.86 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $1.5100 whereas the lowest price it dropped to was $1.3700. The 52-week range on BNGO shows that it touched its highest point at $26.50 and its lowest point at $1.19 during that stretch. It currently has a 1-year price target of $12.33. Beta for the stock currently stands at 2.20.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BNGO was up-trending over the past week, with a rise of 14.06%, but this was down by -9.32% over a month. Three-month performance dropped to -52.29% while six-month performance fell -78.68%. The stock lost -94.30% in the past year, while it has lost -90.00% so far this year. A look at the trailing 12-month EPS for BNGO yields -6.98 with Next year EPS estimates of -2.99. For the next quarter, that number is -0.85. This implies an EPS growth rate of -26.96% for this year and 48.88% for next year.
Float and Shares Shorts:
At present, 38.84 million BNGO shares are outstanding with a float of 38.09 million shares on hand for trading. On Oct 30, 2023, short shares totaled 6.61 million, which was 18.69% higher than short shares on Sep 28, 2023. In addition to Dr. Robert Erik Holmlin M.B.A., Ph.D. as the firm’s President, CEO, Secretary & Director, Mr. Mark Oldakowski serves as its Chief Operating Officer.
Institutional Ownership:
Other institutions hold 7.65% of BNGO, in contrast to 7.39% held by mutual funds. Shares owned by individuals account for 1.31%. As the largest shareholder in BNGO with 4.20% of the stake, The Vanguard Group, Inc. holds 1,483,230 shares worth 1,483,230. A second-largest stockholder of BNGO, BlackRock Fund Advisors, holds 572,148 shares, controlling over 1.62% of the firm’s shares. GMT Capital Corp. is the third largest shareholder in BNGO, holding 530,260 shares or 1.50% stake. With a 2.52% stake in BNGO, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 889,851 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.34% of BNGO stock, is the second-largest Mutual Fund holder. It holds 473,158 shares valued at 0.65 million. SPDR S&P Kensho New Economies Com holds 0.74% of the stake in BNGO, owning 261,255 shares worth 0.36 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BNGO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BNGO analysts setting a high price target of $24.00 and a low target of $6.00, the average target price over the next 12 months is $12.33. Based on these targets, BNGO could surge 1543.84% to reach the target high and rise by 310.96% to reach the target low. Reaching the average price target will result in a growth of 744.52% from current levels.
Summary of Insider Activity:
Insiders traded BNGO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 775,789 while 91,637 shares were sold.
